Search research articles
Contact Us
Filters
Showing results (441-450 of 509) with videos related to
Page
of 51
Sort By:
The New England Journal of Medicine
|
January 19, 2022
Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer
Vicky Makker, Nicoletta Colombo, Antonio Casado Herráez, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 26, 2024
Spatial Profiling of Ovarian Carcinoma and Tumor Microenvironment Evolution under Neoadjuvant Chemotherapy
Elisa Yaniz-Galende, Qinghe Zeng, Juan F Bejar-Grau, et al.
The New England Journal of Medicine
|
December 19, 2019
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer
Isabelle Ray-Coquard, Patricia Pautier, Sandro Pignata, et al.
Gynecologic Oncology
|
July 28, 2022
Paclitaxel with or without pazopanib for ovarian cancer relapsing during bevacizumab maintenance therapy: The GINECO randomized phase II TAPAZ study
Florence Joly, Michel Fabbro, Dominique Berton, et al.
Gynecologic Oncology
|
March 23, 2021
Population exposure-efficacy and exposure-safety analyses for rucaparib in patients with recurrent ovarian carcinoma from Study 10 and ARIEL2
Gottfried E Konecny, Amit M Oza, Anna V Tinker, et al.
The Lancet. Oncology
|
February 4, 2021
Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial
Sandro Pignata, Domenica Lorusso, Florence Joly, et al.
Eclinicalmedicine
|
August 8, 2025
Time-to-pregnancy in patients with previous breast cancer and unexposed women: a prospective exposed-unexposed cohort study
Anne-Sophie Hamy, Agathe Chabassier, Clara Sebbag, et al.
The Lancet. Oncology
|
October 19, 2016
Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial
Olivier Mir, Thomas Brodowicz, Antoine Italiano, et al.
Gynecologic Oncology
|
September 9, 2017
Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2
Amit M Oza, Anna V Tinker, Ana Oaknin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 3, 2025
Atezolizumab With Bevacizumab and Nonplatinum Chemotherapy for Recurrent Ovarian Cancer: Final Results From the Placebo-Controlled AGO-OVAR 2.29/ENGOT-ov34 Phase III Trial
Philipp Harter, Frederik Marmé, Andrés Redondo, et al.
Page
of 51
Search research articles
Search
Showing results (441-450 of 509) with videos related to
Sort By:
Page
of 51
The New England Journal of Medicine
|
January 19, 2022
Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer
Vicky Makker, Nicoletta Colombo, Antonio Casado Herráez, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 26, 2024
Spatial Profiling of Ovarian Carcinoma and Tumor Microenvironment Evolution under Neoadjuvant Chemotherapy
Elisa Yaniz-Galende, Qinghe Zeng, Juan F Bejar-Grau, et al.
The New England Journal of Medicine
|
December 19, 2019
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer
Isabelle Ray-Coquard, Patricia Pautier, Sandro Pignata, et al.
Gynecologic Oncology
|
July 28, 2022
Paclitaxel with or without pazopanib for ovarian cancer relapsing during bevacizumab maintenance therapy: The GINECO randomized phase II TAPAZ study
Florence Joly, Michel Fabbro, Dominique Berton, et al.
Gynecologic Oncology
|
March 23, 2021
Population exposure-efficacy and exposure-safety analyses for rucaparib in patients with recurrent ovarian carcinoma from Study 10 and ARIEL2
Gottfried E Konecny, Amit M Oza, Anna V Tinker, et al.
The Lancet. Oncology
|
February 4, 2021
Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial
Sandro Pignata, Domenica Lorusso, Florence Joly, et al.
Eclinicalmedicine
|
August 8, 2025
Time-to-pregnancy in patients with previous breast cancer and unexposed women: a prospective exposed-unexposed cohort study
Anne-Sophie Hamy, Agathe Chabassier, Clara Sebbag, et al.
The Lancet. Oncology
|
October 19, 2016
Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial
Olivier Mir, Thomas Brodowicz, Antoine Italiano, et al.
Gynecologic Oncology
|
September 9, 2017
Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2
Amit M Oza, Anna V Tinker, Ana Oaknin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 3, 2025
Atezolizumab With Bevacizumab and Nonplatinum Chemotherapy for Recurrent Ovarian Cancer: Final Results From the Placebo-Controlled AGO-OVAR 2.29/ENGOT-ov34 Phase III Trial
Philipp Harter, Frederik Marmé, Andrés Redondo, et al.
Page
of 51